CRISPR-Based Genome Editing in Contemporary Clinical Medicine: Therapeutic Translation, Global Challenges and the Future of Precision Medicine
DOI:
https://doi.org/10.64784/277Keywords:
CRISPR-Cas9, genome editing, gene therapy, precision medicine, base editing, prime editing, clinical medicine, genetic diseases, bioethics, genomic safety, Latin America, personalized medicineAbstract
CRISPR-based genome editing has transformed the therapeutic possibilities of genomic medicine by enabling programmable modification of disease-associated genes and regulatory pathways. This review analyzed the evolution, current clinical applications, emerging therapeutic strategies, safety limitations, ethical challenges, and future perspectives of CRISPR-based technologies within an international framework that incorporates Latin America. An integrative literature review was conducted using scientific evidence published between 2012 and July 2026, with emphasis on peer-reviewed studies indexed in major biomedical databases and relevant international and regulatory documents. The evidence showed a rapid progression from foundational CRISPR-Cas9 research toward base editing, prime editing, ex vivo cellular modification, and direct in vivo genome editing. Clinical translation was most advanced in hematology, particularly in sickle cell disease and transfusion-dependent β-thalassemia, where genome-edited autologous hematopoietic stem and progenitor cells have demonstrated clinically meaningful therapeutic outcomes. Applications in oncology and hereditary transthyretin amyloidosis further demonstrated the feasibility of engineered immune cells and systemic in vivo genome editing. However, broader clinical implementation remains limited by delivery and tissue targeting, off-target and unintended on-target modifications, immunogenicity, manufacturing complexity, long-term safety, regulatory requirements, and accessibility. The international analysis identified heterogeneous capacity for clinical implementation, emphasizing the need to strengthen genomic infrastructure, population representation, professional training, regulatory preparedness, and research participation in Latin America. CRISPR has therefore progressed from an experimental genome-engineering technology to a clinically relevant therapeutic platform, although its future impact will depend on the ability to combine molecular precision and durable therapeutic benefit with rigorous safety assessment, responsible governance, and equitable access across diverse populations and healthcare systems.
References
[1] M. Jinek et al., “A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity,” Science, vol. 337, no. 6096, pp. 816–821, 2012, doi: 10.1126/science.1225829.
[2] L. Cong et al., “Multiplex genome engineering using CRISPR/Cas systems,” Science, vol. 339, no. 6121, pp. 819–823, 2013, doi: 10.1126/science.1231143.
[3] P. Mali et al., “RNA-guided human genome engineering via Cas9,” Science, vol. 339, no. 6121, pp. 823–826, 2013, doi: 10.1126/science.1232033.
[4] J. A. Doudna and E. Charpentier, “The new frontier of genome engineering with CRISPR-Cas9,” Science, vol. 346, no. 6213, Art. no. 1258096, 2014, doi: 10.1126/science.1258096.
[5] A. C. Komor, Y. B. Kim, M. S. Packer, J. A. Zuris, and D. R. Liu, “Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage,” Nature, vol. 533, no. 7603, pp. 420–424, 2016, doi: 10.1038/nature17946.
[6] A. V. Anzalone et al., “Search-and-replace genome editing without double-strand breaks or donor DNA,” Nature, vol. 576, no. 7785, pp. 149–157, 2019, doi: 10.1038/s41586-019-1711-4.
[7] E. A. Stadtmauer et al., “CRISPR-engineered T cells in patients with refractory cancer,” Science, vol. 367, no. 6481, Art. no. eaba7365, 2020, doi: 10.1126/science.aba7365.
[8] Y. Lu et al., “Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer,” Nature Medicine, vol. 26, pp. 732–740, 2020, doi: 10.1038/s41591-020-0840-5.
[9] H. Frangoul et al., “CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia,” New England Journal of Medicine, vol. 384, no. 3, pp. 252–260, 2021, doi: 10.1056/NEJMoa2031054.
[10] J. D. Gillmore et al., “CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis,” New England Journal of Medicine, vol. 385, no. 6, pp. 493–502, 2021, doi: 10.1056/NEJMoa2107454.
[11] H. Frangoul et al., “Exagamglogene autotemcel for severe sickle cell disease,” New England Journal of Medicine, vol. 390, no. 18, pp. 1649–1662, 2024, doi: 10.1056/NEJMoa2309676.
[12] F. Locatelli et al., “Exagamglogene autotemcel for transfusion-dependent β-thalassemia,” New England Journal of Medicine, vol. 390, no. 18, pp. 1663–1676, 2024, doi: 10.1056/NEJMoa2309673.
[13] S. Q. Tsai et al., “GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases,” Nature Biotechnology, vol. 33, no. 2, pp. 187–197, 2015, doi: 10.1038/nbt.3117.
[14] C. E. Nelson and C. A. Gersbach, “Engineering delivery vehicles for genome editing,” Annual Review of Chemical and Biomolecular Engineering, vol. 7, pp. 637–662, 2016, doi: 10.1146/annurev-chembioeng-080615-034711.
[15] D. B. T. Cox, R. J. Platt, and F. Zhang, “Therapeutic genome editing: Prospects and challenges,” Nature Medicine, vol. 21, no. 2, pp. 121–131, 2015, doi: 10.1038/nm.3793.
[16] A. Pickar-Oliver and C. A. Gersbach, “The next generation of CRISPR-Cas technologies and applications,” Nature Reviews Molecular Cell Biology, vol. 20, pp. 490–507, 2019, doi: 10.1038/s41580-019-0131-5.
[17] M. Adli, “The CRISPR tool kit for genome editing and beyond,” Nature Communications, vol. 9, Art. no. 1911, 2018, doi: 10.1038/s41467-018-04252-2.
[18] J. A. Doudna, “The promise and challenge of therapeutic genome editing,” Nature, vol. 578, pp. 229–236, 2020, doi: 10.1038/s41586-020-1978-5.
[19] World Health Organization, Human Genome Editing: Recommendations. Geneva, Switzerland: World Health Organization, 2021.
[20] World Health Organization, Human Genome Editing: A Framework for Governance. Geneva, Switzerland: World Health Organization, 2021.
